FOCUS: A Multicenter, Multinational, Double-blind, 2-Arm, Randomized, Phase 2/3, Study of Physician’s Choice Chemotherapy (PCC) (Weekly Paclitaxel or Pegylated Liposomal Doxorubicin [PLD]) Plus Bevacizumab and CA4P Versus PCC Plus Bevacizumab and Placebo for Subjects with Platinum-Resistant, Recurrent, Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer

Authors
Category Primary study
Registry of TrialsEU Clinical Trials Register
Year 2016
This article has no abstract
Epistemonikos ID: c63fd61ac14fd1eb8ae6cf59631100a3db82ab3e
First added on: Jan 23, 2025